請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/62459
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 錢宗良 | |
dc.contributor.author | Yu-Li Chen | en |
dc.contributor.author | 陳宇立 | zh_TW |
dc.date.accessioned | 2021-06-16T16:02:49Z | - |
dc.date.available | 2016-09-24 | |
dc.date.copyright | 2013-09-24 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-07-03 | |
dc.identifier.citation | Agarwal R, Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3, 502-516.
Alberts DS, Marth C, Alvarez RD, et al (2008) Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecol Oncol 109, 174-181. Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, et al (2001) CD4+ CD25+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J Immunol 166, 3008-3018. Apte RN, Voronov E (2002) Interleukin-1 - a major pleiotropic cytokine in tumor-host interactions. Semin Cancer Biol 12, 277-290. Baecher-Allan C, Anderson DE (2006) Regulatory cells and human cancer. Semin Cancer Biol 16, 98-105. Bast RC Jr. (2003) Status of tumor markers in ovarian cancer screening. J Clin Oncol 21, 200s-205s. Belardelli F, Ferrantini M, Proietti E, et al (2002) Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13, 119-134. Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11, 889-896. Boon T, Cerottini JC, Van den Eynde B, et al (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12, 337-365. Candido EB, Silva LM, Carvalho AT, et al (2012) Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer. Reprod Sci. [Epub ahead of print] Cannistra SA (2004). Cancer of the ovary. N Engl J Med 351, 2519-2529. Cheng WF, Hung CF, Chai CY, et al (2007) Generation and characterization of an ascitogenic mesothelin-expressing tumor model. Cancer 110, 420-431. Cheng WF, Hung CF, Hsu KF, et al (2001) Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments. Hum Gene Ther 12, 235-252. Cheng WF, Hung CF, Chai CY, et al (2001) Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. J Immunol 166, 6218-6226. Cheng WF, Lee CN, Su YN, et al (2005) Induction of human papillomavirus type 16-specific immunologic responses in a normal and a human papillomavirus-infected populations. Immunology 115, 136-149. Chen CA, Ho CM, Chang MC, et al (2010) Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol Ther 18, 1233-1243. Chen YL, Chang MC, Chen CA, et al (2012) Depletion of regulatory T lymphocytes reverses the imbalance between pro- and anti-tumor immunities via enhancing antigen-specific T cell immune responses. PLoS One 7, e47190. Chen YL, Chang MC, Huang CY, et al (2012) Serous Ovarian Carcinoma Patients with High Alpha-Folate Receptor Had Reducing Survival and Cytotoxic Chemo-response. Mol Oncol 6, 360-369. Chu CS, Kim SH, June CH, et al (2008) Immunotherapy opportunities in ovarian cancer. Expert Rev Anticancer Ther 8, 243-257. Clarke B, Tinker AV, Lee CH, et al (2009) Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 22, 393-402. Colombo MP, Trinchieri G (2002) Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13, 155-168. Curiel TJ, Coukos G, Zou L, et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10, 942-949. De Palma M, Venneri MA, Galli R, et al (2005) Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8, 211-226. den Boer AT, van Mierlo GJ, Fransen MF, et al (2005) CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T cell responses in tumor-bearing hosts. Cancer Res 65, 6984-6989. Dighe AS, Richards E, Old LJ, et al (1994) Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1, 447-456. DiSaia PJ, Bloss JD (2003) Treatment of ovarian cancer: new strategies. Gynecol Oncol 90, S24-S32. Dong C (2006) Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat Rev Immunol 6, 329-333. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22, 329-360. Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6, 836-848. Dunn GP, Bruce AT, Ikeda H, et al (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol 3, 991-998. Fahlen L, Read S, Gorelik L, Hurst SD, Coffman RL, et al (2005) T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells. J Exp Med 201, 737-746. Forni G, Fujiwara H, Martino F, et al (1988) Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy. Cancer Metastasis Rev 7, 289-309. Freeman CM, Chiu BC, Stolberg VR, Hu J, Zeibecoglou K, et al (2005) CCR8 is expressed by antigen-elicited, IL-10-producing CD4+CD25+ T cells, which regulate Th2-mediatedgranuloma formation in mice. J Immunol 174, 1962-1970. Fridlender ZG, Sun J, Kim S, et al (2009) Polarization of tumor-associated neutrophil phenotype by TGF-b: “N1” versus “N2” TAN. Cancer Cell 16, 183-194. Gabrilovich DI, Chen HL, Girgis KR, et al (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2, 1096-1103. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9, 162-174. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12, 253-268. Ghiringhelli F, Menard C, Terme M, et al (2005) CD4+ CD25+ regulatory T cell inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J Exp Med 202, 1075-1085. Giuntoli RL 2nd, Webb TJ, Zoso A, et al. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res 29, 2875-2884. Golumbek PT, Lazenby AJ, Levitsky HI, et al (1991) Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254, 713-716. Gonzalez-Diego P, Lopez-Abente G, Pollan M, et al (2000) Time trends in ovarian cancer mortality in Europe (1955-1993): effect of age, birth cohort and period of death. Eur J Cancer 36, 816-824. Gresser I, Belardelli F (2002) Endogenous type I interferons as a defense against tumors. Cytokine Growth Factor Rev 13, 111-118. Grivennikov S, Karin M (2008) Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 13, 7-9. Grossman WJ, Verbsky JW, Barchet W, et al (2004) Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21, 589-601. Hallermalm K, Seki K, De Geer A, et al (2008) Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes. J Immunol 180, 3766-3774. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674. Hix LM, Shi YH, Brutkiewicz RR, et al (2011) CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis. PLoS ONE 6, e20702. Ikeda H, Old LJ, Schreiber RD (2002) The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13, 95-109. Imai H, Saio M, Nonaka K, et al (2007) Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci 98, 416-423. International Federation of Gynecology and Obstetrics (1971) Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand 50, 1-7. International Federation of Gynecology and Obstetrics (1987) Changes in definitions of clinical staging for carcinoma of the cervix and ovary: International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol 156, 263-264. Ioannides CG, Platsoucas CD, Rashed S, Wharton JT, Edwards CL, et al (1991) Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 51, 4257-4265. Jacobs JF, Idema AJ, Bol KF et al (2009) Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol 11, 394-402. Jacobs JF, Nierkens S, Figdor CG, et al (2012) Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 13, e32-42. Jemal A, Bray F, Center MM,et al (2011) Global cancer statistics. CA Cancer J Clin 61, 69-90. Kandalaft LE, Singh N, Liao JB, et al (2010) The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. Gynecol Oncol 116, 222-33. Kaplan DH, Shankaran V, Dighe AS, et al (1998) Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95, 7556-7561. Karin, M (2006) Nuclear factor-κB in cancer development and progression. Nature 441, 431-436. Kiniwa Y, Miyahara Y, Wang HY et al (2007) CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 13, 6947-6958. Koebel CM, Vermi W, Swann JB, et al (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903-907. Kooi S, Freedman RS, Rodriguez-Villanueva J, et al (1993) Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigenindependent cytokine production by ovarian tumor cells. Lymphokine Cytokine Res 12, 429-437. Kryczek I, Banerjee M, Cheng P, et al (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114, 1141-1149. Kryczek I, Wei S, Zhu G, et al (2007) Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 67, 8900-8905. Lane D, Matte I, Rancourt C, et al (2011) Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer 11, 210. Langowski JL, Zhang X, Wu L, et al (2006) IL-23 promotes tumour incidence and growth. Nature 442, 461-465. Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, et al (2007) Tumor-derived CD4(+)CD25(+) regulatoryTcell suppression of dendritic cell function involves TGF-h and IL-10. Cancer Immunol Immunother 56, 48 -59. Lawrence CW, Braciale TJ (2004) Activation, differentiation and migration of naive virus-specific CD8+ T cells during pulmonary influenza virus infection. J Immunol 173, 1209-1218. Leffers N, Gooden MJ, de Jong RA (2009) Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunothe 58, 449-459. Lejeune FJ (2002) Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. J Clin Invest 110, 433-435. Li Q, Carr A, Ito F, et al (2003) Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy. Cancer Res 63, 2546-2552. Liao CW, Chen CA, Lee CN, et al (2005) Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects. Cancer Res 65, 9089-9098. Malkasian GD Jr, Melton LJ 3rd, O'Brien PC,et al (1984) Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obstet Gynecol 149, 274-284. Malmberg KJ, Levitsky V, Norell H, et al (2002) IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest 110, 1515-1523. Mantovani A, Allavera P, Sica A et al (2008) Cancer-related inflammation. Nature 454, 436-444. Marth C, Windbichler GH, Hausmaninger H, et al (2006) Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study. Int J Gynecol Cancer 16, 1522-1528. Miller CH, Maher SG, Young HA (2009) Clinical Use of Interferon-gamma. Ann N Y Acad Sci 1182, 69-79. Nakamura K, Kitani A, Fuss I, et al (2004) TGF-β 1 plays an important role in the mechanism of CD4+ CD25+ regulatory T cell activity in both humans and mice. J Immunol 172, 834-842. Nakamura T, Yoshitani M, Rigby H, et al (2004) Sterilized, freeze-dried amniotic membrane: a useful substrate for ocular surface reconstruction. Invest Ophthalmol Vis Sci 45, 93-99. Nishikawa H, Sakaguchi S (2010) Regulatory T cells in tumor immunity. Int J Cancer 127, 759-767. Olkhanud PB, Damdinsuren B, Bodogai M et al (2011) Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells. Cancer Res 71, 3505-3015. Onizuka S, Tawara I, Shimizu J, et al (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor a) monoclonal antibody. Cancer Res 59, 3128-3133. Pfleiderer A (1984) Diagnosis and staging of ovarian cancer. J Cancer Res Clin Oncol 107, 81-88. Piconese S, Valzasina B, Colombo MP (2008) OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 205, 825-839. Platonova S, Cherfils-Vicini J, Damotte D et al (2011) Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 71, 5412-5322. Pujade-Lauraine E, Guastalla JP, Colombo N, et al (1996) Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 14, 343-350. Quezada SA, Peggs KS, Simpson TR, et al (2011) Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev 241, 104-118. Raspollini MR, Castiglione F, Rossi DD, et al (2005) Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol 16, 590-596. Rocconi RP, Matthews KS, Kemper MK, et al (2009) The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer. Gynecol Oncol 114, 242-245. Roord ST, de Jager W, Boon L, et al (2008) Autologous bone marrow transplantation in autoimmune arthritis restores immune homeostasis through CD4+CD25+Foxp3+ regulatory T cells. Blood 111, 5233-5241. Rosenberg SA, Lotze MT (1986) Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol 4, 681-709. Rustin GJ (1992) Tumour markers for ovarian cancer. Eur J Cancer 28, 2-3. Sakaguchi S (2004) Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune response. Annu Rev Immunol 22, 531-532. Sakaguchi S, Miyara M (2007) Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 13, 108-116. Sato E, Olson SH, Ahn J, et al (2005) Intra-epithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102, 18538-18543. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331, 1565-1570. Shankaran V, Ikeda H, Bruce AT, et al (2001) IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107-1111. Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163, 5211-5218. Smyth MJ, Dunn GP, Schreiber RD (2006) Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90, 1-50. Street SE, Cretney E, Smyth MJ (2001) Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 97, 192-197. Street SE, Trapani JA, MacGregor D, et al (2002) Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 196, 129-134. Swenerton KD, Hislop TG, Spinelli J, et al (1985) Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol 65, 264-270. Szlosarek PW, Balkwill FR (2003) Tumour necrosis factor α: a potential target for the therapy of solid tumours. Lancet Oncol 4, 565-573. Tomsova M, Melichar B, Sedlakova I, et al (2008) Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 108, 415-420. Trinchieri G (1995) Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13, 251-276. Tsuji NM, Mizumachi K, Kurisaki J (2003) Antigen-specific, CD4+CD25+ regulatoryTcell clones induced in Peyer’s patches. Int Immunol 15, 525-534. Valzasina B, Guiducci C, Dislich H, et al (2005) Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 105, 2845-2851. Vesely MD, Kershaw MH, Schreiber RD, et al (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29, 235-271. Vivier E, Ugolini S, Blaise D, et al (2012) Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 12, 239-252. Voronov E, Shouval DS, Krelin Y, et al (2003) IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl Acad Sci USA 100, 2645-2650. Watkins SK, Zhu Z, Riboldi E et al (2011) FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest 121, 1361-1372. Windbichler GH, Hausmaninger H, Stummvoll W, et al (2000) Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 82, 1138-1144. Wolf D, Wolf AM, Rumpold H, et al (2005) The expression of the regulatory T cell-specific fork-head box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11, 8326-8331. Workman CJ, Rice DS, Dugger KJ, et al (2002) Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). Eur J Immunol 32, 2255-2263. Wynn TA (2005) T(H)-17: a giant step from T(H)1 and T(H)2. Nat Immunol 6, 1069-1070. Yigit R, Figdor CG, Zusterzeel PL, et al (2011) Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer. Eur J Cancer 47, 1883-1889. Yigit R, Massuger LF, Figdor CG, et al (2010) Ovarian cancer creates a suppressive micro-environment to escape immune elimination. Gynecol Oncol 117, 366-372. Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nature Rev Immunol 7, 41-51. Zhang L, Conejo-Garcia JR, Katsaros D, et al (2003) Intra-tumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348, 203-213. Zhu J, Paul WE (2010) Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors. Immunol Rev 238, 247-262. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/62459 | - |
dc.description.abstract | 根據台灣衛生署的統計,卵巢癌的發生率逐年升高,其死亡率在婦女的惡性腫瘤中名列第一。卵巢癌的五年總存活率為45%,依不同期別及不同組織型態而有不同。若腫瘤只出現在卵巢或侷限於骨盆腔時,其存活率分別為93%及69%,但大部分病患(約68%)在診斷時即出現遠端轉移,其五年存活率便只剩30%。
在很多文獻已經證實,卵巢癌細胞是具有誘發出宿主抗腫瘤的免疫能力。當身體內增進及抑制免疫反應的機制失衡時,體內對抗腫瘤的免疫力便會被破壞。藉由卵巢癌病人檢體及其動物模式的分析,可以了解卵巢癌生成過程中宿主促進及抑制免疫力的動態改變,同時可以發現在腫瘤形成過程中,與病人預後相關以及具有可逆性的因子。 我們在動物實驗中發現,當抑制調控性T細胞的功能,可以矯正在腫瘤形成過程中,宿主體內增進及抑制免疫反應失衡的情況,並產生有效的抗腫瘤效果。透過病人檢體的分析,能夠發現,當卵巢癌病患的腹水中,如果表現較高的干擾素-γ,這些病人將會有較差的存活率。因此,探究新的方式來抑制調控性T細胞的功能,可以成為癌症免疫治療的一個重要方式。此外,卵巢癌病患的腹水中,干擾素-γ的表現程度,可以成為與病人預後相關的標記,也可以成為日後與干擾素-γ相關之癌症免疫治療的重要參考。 | zh_TW |
dc.description.abstract | According to the statistics of the Department of Health, the incidence of ovarian cancer increased in recent years and the mortality rate is highest in all gynecologic malignancies in Taiwan. The 5- year relative survival rate is 45% overall, but varies by stage and histologic type. Women with the localized or regional diseases such as pelvic cavity have the survival rates of 93% and 69%, respectively, but most cases (~68%) diagnosed as distant stage have overall 5-year relative survival rate of 30%.
Ovarian carcinoma has been proven to be immunogenic in the previous reports. When the imbalance between immune activation and suppression occurs, the immune responses against tumor cells are destroyed. Through the analysis of clinical specimens of ovarian cancer patients and animal model of ovarian carcinoma, the kinetic alterations of host immunities and their reversible and prognostic factors in the progression of ovarian cancer could be identified. In the animal experiments, depletion of regulatory T (Treg) cells can correct the imbalance of immunologic profiles and generate potent anti-tumor effects. The patients with ovarian cancer and higher interferon-gamma (IFN-γ) levels in the ovarian cancer-associated ascites have poorer survival. Therefore, the exploration of new strategies for effective depletion of Treg cells could become an important modality for cancer immunotherapy. In addition, IFN-γ expression levels in ascites could be a prognostic marker and a potential reference for future immunotherapy targeting IFN-γ. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T16:02:49Z (GMT). No. of bitstreams: 1 ntu-102-D96446003-1.pdf: 4645642 bytes, checksum: 30c1c81c53b90d9b8b8c40fa2b543745 (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | Contents of Dissertation
Acknowledgement--------------------------------------------i Table of contents----------------------------------------1-2 Summary of dissertation in Chinese-------------------------3 Summary of dissertation in English-----------------------4-5 Chapter 1. General Introduction----------------------------6 Characteristics of tumor immunology---------------------7-11 Tumor immunology in ovarian carcinoma------------------11-14 Specific aims of current study-------------------------14-16 Chapter 2. Depletion of Regulatory T Lymphocytes Reverses the Imbalance between Pro- and Anti-Tumor Immunities via Enhancing Antigen-specific T Cell Immune Responses--------17 Abstract-----------------------------------------------18-19 Introduction-------------------------------------------20-22 Materials and methods----------------------------------23-31 Results------------------------------------------------32-43 Discussions--------------------------------------------44-49 Figures------------------------------------------------50-76 Chapter 3. Interferon-gamma in Ascites Could Be a Predictive Biomarker of Outcome in Ovarian Carcinoma------77 Abstract-----------------------------------------------78-79 Introduction-------------------------------------------80-82 Materials and methods----------------------------------83-87 Results------------------------------------------------88-92 Discussion---------------------------------------------93-97 Figures and Tables------------------------------------98-103 Chapter 4. Conclusions and Future Prospectives-----------104 Conclusions----------------------------------------------105 Prospectives-----------------------------------------106-109 Bibliography---------------------------------------------110 References-------------------------------------------111-127 Appendix-------------------------------------------------128 | |
dc.language.iso | en | |
dc.title | 透過卵巢癌病人檢體及動物模式探討卵巢癌生成過程中宿主免疫力的動態改變並評估其可逆之因素 | zh_TW |
dc.title | Exploration of the kinetic alterations of host immunities and their reversible factors in the progression of ovarian cancer through the specimens of ovarian cancer patients and the animal model of ovarian carcinoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 盧國賢,陳祈安,鄭文芳,周振陽,何志明 | |
dc.subject.keyword | 卵巢癌,腫瘤免疫, | zh_TW |
dc.subject.keyword | ovarian carcinoma,tumor immunology, | en |
dc.relation.page | 128 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2013-07-04 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 解剖學暨細胞生物學研究所 | zh_TW |
顯示於系所單位: | 解剖學暨細胞生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 4.54 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。